Compare GVA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GVA | ACAD |
|---|---|---|
| Founded | 1922 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.6B |
| IPO Year | 1990 | 2004 |
| Metric | GVA | ACAD |
|---|---|---|
| Price | $116.14 | $27.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 22 |
| Target Price | ★ $105.00 | $29.05 |
| AVG Volume (30 Days) | 634.1K | ★ 1.4M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | 68.53 | ★ 98.53 |
| EPS | ★ 3.67 | 1.54 |
| Revenue | ★ $4,236,312,000.00 | $1,047,118,000.00 |
| Revenue This Year | $11.29 | $15.16 |
| Revenue Next Year | $10.61 | $11.42 |
| P/E Ratio | $31.38 | ★ $17.62 |
| Revenue Growth | 6.87 | ★ 12.69 |
| 52 Week Low | $69.08 | $13.40 |
| 52 Week High | $115.88 | $27.73 |
| Indicator | GVA | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 79.75 | 70.21 |
| Support Level | $107.77 | $26.38 |
| Resistance Level | $110.31 | $27.73 |
| Average True Range (ATR) | 2.43 | 0.81 |
| MACD | 1.04 | 0.11 |
| Stochastic Oscillator | 89.23 | 87.25 |
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.